Login / Signup

Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.

Morgan StuartLinda JohnsonSarah HaniganSteven W PipeShih-Hon Li
Published in: Journal of thrombosis and haemostasis : JTH (2020)
The BIOPHEN ANTI-IIa assay is suitable for patients transitioning off apixaban or rivaroxaban.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • venous thromboembolism
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • atrial fibrillation
  • peritoneal dialysis
  • high throughput
  • growth factor
  • patient reported